Dergiler / Koşuyolu Heart Journal / 2016 / Cilt: 19 - Sayı: 1

ST Yükselmesiz Akut Koroner Sendrom Hastalarında TIMI Risk Skoru ile Hemoglobin Değeri Arasındaki İlişkinin Değerlendirilmesi

Evaluation of the Relationship Between Hemoglobin Levels and Thrombolysis in Myocardial Infarction Risk Score in Patients with Non-ST Elevation Acute Coronary Syndrome

Sayfa
32–36
Yayın Tarihi
2016-04-04
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bulgular: Geliş hemoglobin seviyesi (g/dL) düşük, orta ve yüksek TIMI risk grubunda sırasıyla (13.5 ± 1.9, 12.5 ± 1.9, 11.3 ± 1.9, p< 0.001) olarak saptandı.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536859905 -1073711037 9 0 511 0;} @font-face {font-family:"MS 明朝"; mso-font-charset:78; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536870145 1073743103 0 0 415 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Giriş: ST yükselmesiz akut koroner sendrom hastalarının geliş hemoglobin seviyesi ile TIMI risk skoru arasındaki ilişki araştırıldı.
📊
Temel Bulgular & Veri:Hastalar ve Yöntem: ST yükselmesiz akut koroner sendromlu 286 hasta çalışmaya dahil edildi.
💡
Sonuç & Katkı:Bulgular: Geliş hemoglobin seviyesi (g/dL) düşük, orta ve yüksek TIMI risk grubunda sırasıyla (13.5 ± 1.9, 12.5 ± 1.9, 11.3 ± 1.9, p< 0.001) olarak saptandı.
🔬Tür:Araştırma Makalesi
📍Kapsam:286 hasta
⚙️Değişkenler:Miyokart infarktüsü · hemoglobinler · akut koroner sendrom

Özet

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536859905 -1073711037 9 0 511 0;} @font-face {font-family:"MS 明朝"; mso-font-charset:78; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536870145 1073743103 0 0 415 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Giriş: ST yükselmesiz akut koroner sendrom hastalarının geliş hemoglobin seviyesi ile TIMI risk skoru arasındaki ilişki araştırıldı. Hastalar ve Yöntem: ST yükselmesiz akut koroner sendromlu 286 hasta çalışmaya dahil edildi. Tüm hastaların geliş anında hemoglobin ve biyokimyasal parametreleri çalışıldı. Hastalar TIMI risk skoruna göre düşük, orta ve yüksek risk olarak 3 gruba ayrıldı. Bulgular: Geliş hemoglobin seviyesi (g/dL) düşük, orta ve yüksek TIMI risk grubunda sırasıyla (13.5 ± 1.9, 12.5 ± 1.9, 11.3 ± 1.9, p< 0.001) olarak saptandı. Hemoglobin seviyesi ve TIMI risk skoru arasında orta düzeyde negatif korelasyon bulundu (r: -0.408, p< 0.001). Tek değişkenli regresyon analizinde TIMI risk skoru artışı ile geliş hemoglobin seviyelerinin önemli derecede düşük olduğu saptandı (Estimate; -0.406, p< 0.001, %95 GA[-0.521-(-0.290)]. Sonuç: ST yükselmesiz akut koroner sendrom ile hastaneye yatırılan hastaların risk skoru attıkça geliş hemoglobin seviyelerinin bağlantılı olarak düşük olduğu tespit edildi. Basit ve yaygın bir test olarak kullanılan hemoglobin seviyesi, ST yükselmesiz akut koroner sendrom hastalarının geliş anındaki risk durumunu belirlemede kullanılabilir.

Abstract

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536859905 -1073711037 9 0 511 0;} @font-face {font-family:"MS 明朝"; mso-font-charset:78; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536870145 1073743103 0 0 415 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Introduction: The relationship between hemoglobin (Hb) levels at admission and the thrombolysis in myocardial infarction (TIMI) risk score in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) was investigated. Patients and Methods: In total, 286 NSTE-ACS patients were included in the study. Hb levels and biochemical parameters were measured at admission. The patients were grouped into the following three groups according to the TIMI risk score: low-intermediate-, and high-risk groups. Results: Hb levels (in g/dL) at admission in low-, intermediate-, and high-risk groups were 13.5 ± 1.9, 12.5 ± 1.9, and 11.3 ± 1.9, respectively (p < 0.001). We found a negative moderate correlation between Hb levels and TIMI risk scores (r= -0.408, p < 0.001). In univariate regression analysis, it was found that with the increase in the TIMI risk score, Hb levels at admission were significantly reduced (estimate= -0.406; p< 0.001; 95% confidence interval; -0.521 to -0.290). Conclusion: We found that as the TIMI risk score of patients admitted to hospital presenting with NSTE-ACS increased, their Hb levels at admission correspondingly decreased. Thus, the simple and commonly measured Hb level can be a useful parameter in stratifying the risks of patients presenting with NSTE-ACS during admission.

🔖

Bu Makaleye Atıf Yap

GEÇMEN, Ç., GÜLER, E., GÜLER, G. B., ELVERAN, A., GÜNEŞ, H. M., AGUŞ, H. Z., KARACA, O., KELEŞ, N., ESEN, Ö., ESEN, A. M. (2016). ST Yükselmesiz Akut Koroner Sendrom Hastalarında TIMI Risk Skoru ile Hemoglobin Değeri Arasındaki İlişkinin Değerlendirilmesi. Koşuyolu Heart Journal, Cilt: 19 - Sayı: 1, 32–36. https://ajindex.com/articles/63952

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146
  2. Tello-Montoliu A, Marín F, Roldán V, Mainar L, López MT, Sogorb F, et al. Multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med 2007;262:651-8
  3. Guler E, Gecmen C, Guler GB, Karaca O, Agus HZ, Gunes HM, et al. Adding lipoprotein (a) levels to the GRACE score to predict prognosis in patients with non-ST elevation acute coronary syndrome. Kardiol Pol 2013;71:695-701
  4. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM, et al. Transfusion practice and outcomes in non–ST-segment elevation acute coronary syndromes. Am Heart J 2008;155:1047-53
  5. Lipsic E, Van Der Horst IC, Voors AA, van der Meer P, Nijsten MW, van Gilst WH, et al. Hemoglobin levels and 30 day mortality in patients after myocardial infarction. Int J Cardiol 2005;100:289-92
  6. Kunadian V, Mehran R, Lincoff AM, Feit F, Manoukian SV, Hamon M, et al. Cox DA. Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). Am J Cardiol 2014;114:1823-9
  7. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:109
  8. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42
  9. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005;111:2042-9
  10. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Ab